AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00911612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert capsule matching the study drug, given twice daily
Trial: NCT00497289
Drug: Lipofundin MCT/LCT 20 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily i.v. infusion for up to 5 days
Trial: NCT00497289
Drug: Lipidem 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily i.v. infusion for up to 5 days
Trial: NCT03973411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacients will receibe standard spinal anesthesia
Trial: NCT00708214
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 at high and medium dosages
Trial: NCT02041117
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
Trial: NCT01073904
Drug: Postinor 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1.5 mg tablet
Trial: NCT01480947
Drug: Bio-three
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
Trial: NCT02579564
Drug: Oncorine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04069325
Drug: simiaowan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pills, 6g twice daily (BID), oral, 12 weeks
Trial: NCT04069325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pills, 6g twice daily (BID), oral, 12 weeks
Trial: NCT01250873
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po administration
Trial: NCT04594369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib-matching oral tablet.
Trial: NCT01214083
Drug: N-acetylcysteine + high-dose naltrexone (150 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be evaluated weekly for 12 weeks.
Trial: NCT03181802
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
Trial: NCT00194688
Drug: H. pylori treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03406819
Drug: Heparinized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion 2ml for single time
Trial: NCT00169000
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID
Trial: NCT01728519
Drug: AllerT SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
Trial: NCT01728519
Drug: AllerT ID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
Trial: NCT01728519
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
Trial: NCT02949843
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive other treatment
Trial: NCT02949843
Drug: Tyrosine Kinase Inhibitor
RxNorm normalized name: Protein-tyrosine kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02524743
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
Trial: NCT01307800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03633305
Drug: Hypnotics
RxNorm normalized name: HYPNOTICS AND SEDATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.
Trial: NCT01490879
Drug: Nexagon® Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
Trial: NCT01490879
Drug: Nexagon® Medium Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
Trial: NCT01490879
Drug: Nexagon® High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
Trial: NCT01490879
Drug: Nexagon® vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
Trial: NCT00650325
Drug: Zoloft® Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fasting
Trial: NCT00147667
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01303406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00347477
Drug: HyperHAES vs. RA-solution/NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02189304
Drug: Symbicort Turbohaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Turbohaler taken as 2 inhalations
Trial: NCT03500783
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
Trial: NCT04172259
Drug: Doxorubicin liposome
RxNorm normalized name: Doxorubicin liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD
Trial: NCT04172259
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CTX
Trial: NCT01225081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03075878
Drug: ALXN1830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IV infusion.
Trial: NCT02118727
Drug: Placebo (for Memantine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Trial: NCT00577980
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
Trial: NCT00449137
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Trial: NCT00449137
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Trial: NCT03804229
Drug: Placebo soft capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
Trial: NCT04224415
Drug: C225+CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1
Trial: NCT04053699
Drug: Von Willebrand Factor-Containing Product
RxNorm normalized name: von Willebrand factor-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
Trial: NCT01328145
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg /day
Trial: NCT02586610
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
Trial: NCT01527695
Drug: ER tablet 100 mg AZD3241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days
Trial: NCT01527695
Drug: Placebo for AZD3241 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days
Trial: NCT00378508
Drug: Placebo Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02064504
Drug: GSK961081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white to off white powder
Trial: NCT03836885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
Trial: NCT02584257
Drug: placebo ProAir HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00713791
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period 1: 10mg oral solution
Trial: NCT00713791
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Trial: NCT00713791
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Trial: NCT00713791
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
Trial: NCT04065971
Drug: 2LHERP®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT04065971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT03560011
Drug: immunoglobulin IV
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
Trial: NCT00849511
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
Trial: NCT02865785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
Trial: NCT00868894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application
Trial: NCT01697826
Drug: ClinSupV3ER- Extended release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
Trial: NCT00878800
Drug: PXD101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in combination with doxorubicin (BelDox)
Trial: NCT00878800
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered in combination with PXD101 (BelDox)
Trial: NCT01172223
Drug: Myocet (Non-pegylated liposomal doxorubicin (NPLD))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 i.v. day 1 q3 weeks
Trial: NCT02610543
Drug: UCB5857
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
Trial: NCT02610543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
Trial: NCT00613691
Drug: SPI-1620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
Trial: NCT02463929
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Injection
Trial: NCT00254800
Drug: ethinyl estradiol and levonorgestrel; exenatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
Trial: NCT03648437
Drug: Paracetamol 10Mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drug
Trial: NCT03648437
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard therapy
Trial: NCT03648437
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard therapy
Trial: NCT03396315
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
Trial: NCT01035164
Drug: F-18 FEDAA1106 (BAY85-8101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
Trial: NCT02452632
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02452632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02380625
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
Trial: NCT01270464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
Trial: NCT03526536
Drug: IV Novolin R human insulin
RxNorm normalized name: insulin, regular, human Injectable Solution [Novolin R]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
Trial: NCT02372812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00751049
Drug: PhXA41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Trial: NCT00004875
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00441376
Drug: ThermoDox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
Trial: NCT03214380
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03611777
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT01872598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01872598
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
Trial: NCT03788434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
Trial: NCT02490787
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin)
Trial: NCT04582929
Drug: Neuronox ® Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuronox ® 50 or 100 unit intramuscular injection
Trial: NCT03473639
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
Trial: NCT02837939
Drug: Human derived Transfer factor
RxNorm normalized name: brain-derived neurotrophic factor, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~* 3 x TF in first week: day 1,3,5~* 2 x TF in week 2: day 8 , 11~* 1 xTF in week 3 and 4 : day 15, 22~* 1 x TF once a month up to 6 month
Trial: NCT00270153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg enalapril-matching placebo daily for 6 months
Trial: NCT01448109
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
Trial: NCT00452673
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
Trial: NCT02218099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03650543
Drug: amoxicillin clarithromycin omeprazole 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
Trial: NCT03650543
Drug: amoxicillin clarithromycin omeprazole 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
Trial: NCT00790244
Drug: doxorubicin , ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week